Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing ...

The Parkinson’s disease (PD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK and Japan ...

Shares of US clinical-stage company Eledon Pharmaceuticals shot up 9.9% to close at $3.44 yesterday, after it announced ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Ireland-headquartered Jazz Pharmaceuticals’ ...

Swiss generics and biosimilar major Sandoz today presented its financial results for the first half of 2025. and reiterated ...

Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

Germany’s Merck KGaA (MRK: DE) has reported second quarter earnings that missed analyst expectations. The life sciences company’s earnings before interest, taxes, depreciation and amortization (EBITDA ...

The initial small tariff on pharmaceutical imports will be increased to 150% within 18 months and eventually to 250%, according to President Trump’s comments in a CNBC interview.

Hungary’s largest drugmaker Gedeon Richter has announced its financial results for the second quarter and first half year of 2025.

A clinical-stage biotech company developing antibody therapies targeting immune-related diseases, especially inflammatory bowel disease (IBD).